Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Squamous Cell Carcinoma of Head and Neck 31Lung Neoplasms 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Carcinoma, Transitional Cell 8Neoplasm Metastasis 7Mouth Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Recurrence 6Neoplasms 6Melanoma 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 6Mesothelioma, Malignant 5Medulloblastoma 5Laryngeal Neoplasms 5

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Cisplatin 1Central Venous Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Infratentorial Neoplasms × Cisplatin × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡